Drawing for ABECMA

USPTO serial 88202247

ABECMA

Reviewed by CopyMark Law Group

Reg. 5958800Status 702Registered
Filing date
Status date
Registration date
Jan 14, 2020
Examiner
PIERCE, ALEXANDRA
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with ABECMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Marilyn F. Kelly

Marilyn F. Kelly Bristol-Myers Squibb CompanyPO BOX 4000Trademark Dept., Mailstop D.4243PRINCETON, NJ 08648

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for use in the treatment of multiple myeloma, blood disease, cancer, diseases in the fields of oncology, immunology and [ inflammation ] ; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune systemACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 17, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Mar 17, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Mar 16, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 12, 2025E815TEAS SECTION 8 & 15 RECEIVED—
Jan 14, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Dec 9, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 9, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 9, 2022EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Dec 9, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 9, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 9, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 14, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 29, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 29, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 9, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 19, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 16, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Sep 16, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 16, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 16, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 5, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 5, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 3, 2019ALIEASSIGNED TO LIE—
Aug 22, 2019ALIEASSIGNED TO LIE—
Aug 14, 2019ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Feb 26, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Feb 26, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Feb 26, 2019CNSLSUSPENSION LETTER WRITTEN—
Feb 25, 2019DOCKASSIGNED TO EXAMINER—
Feb 22, 2019PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Dec 11, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 24, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance